Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to start review
Explore by Goal
"The science of today is the technology of tomorrow."
- Edward Teller
Quick Explanation
Copied
Core takeaway: In a single-center 11-year experience (1990–2001; n=155 recipients; n=165 allografts), actuarial patient survival was reported as 75% (1y), 54% (5y), 42% (10y), with liver-containing grafts showing better long-term prognosis than intestine-only grafts.
Long Explanation
Paper Review (Science-Grade, Skeptical): Clinical Intestinal Transplantation: A Decade of Experience at a Single Center
Annals of Surgery (Accepted April 26, 2001). DOI: 10.1097/00000658-200109000-00014
All plotted values below are taken directly from the paper’s reported survival percentages and event rates (not re-estimated).
Evidence note (skeptical): survival is actuarial (Kaplan–Meier) and reported at discrete timepoints; era changes and multiple concurrent management modifications make attribution to any single intervention uncertain. The paper explicitly describes multiple co-evolving strategies during and after a 1994 moratorium.
Cohort composition (reported)
Numbers come from the Methods description of 155 patients receiving 165 intestinal allografts.
Era changes (1990–1994 vs post-moratorium 1995–2001)
The paper reports rejection within 30 postoperative days: 85% (1990–1994) vs 67% (1995–2001).
Major causes of death (reported)
Values are taken from the paper’s Table 4 “Cause of death after intestinal transplantation”.
Virus-associated syndromes (reported)
The paper states 30 of 155 patients developed PTLD (19%).
The paper reports PTLD fatality 44% earlier vs 8% after 1994, in parallel with improved PTLD detection/management.
What the paper claims vs what the data can actually support
1) Improved survival over time
The authors report that 1-year actuarial patient survival improved post-moratorium: 71% (early cohort, n=62) vs 78% (post-1994 cohort, n=93), with a reported P=0.03, and they also report improved rejection-related outcomes and reductions in ICU/hospital stay.
Skeptical constraint: Because multiple interventions changed simultaneously after 1994 (daclizumab, bone marrow augmentation, earlier viral surveillance, and later irradiation), this is an era effect, not a clean test of a single causal mechanism. The paper itself notes that therapeutic efficacy cannot be definitively claimed for these modifications.
2) Liver-containing grafts appear more protective
The authors report better long-term prognosis for recipients of liver plus intestine than for intestine alone, including the “lowest risk of graft loss from rejection” (P=0.001).
Skeptical constraint: Graft-type comparisons can be confounded by baseline risk (patients requiring composite grafts may differ in severity, urgency, and complications). The paper includes discussion/argumentation about non-immunologic risk factors eroding any “liver protective effect,” suggesting the observed differences may not be purely immunological.
3) Rejection and chronic rejection risk differ by graft category and strategy
The paper reports that cumulative risk of graft loss from acute and chronic rejection of intestine-only grafts was significantly greater than composite visceral grafts containing liver (P=0.00001), and that chronic rejection cumulative risk was higher in isolated intestine vs liver-containing composite grafts (1y and 5y rates reported, plus strong P-value).
4) Virus-associated syndromes: early detection and preemptive management are central
The paper emphasizes improved early detection for EBV (PCR in peripheral blood) and CMV (PP65 antigenemia), along with preemptive/adjunct antiviral strategies in high-risk patients; it reports no CMV-associated deaths since 1994 despite broad use of CMV-positive donors and describes reduced CMV disease risk.
Critical limitations & blind spots (must read)
Non-randomized, single-center observational design with substantial management evolution over time, making causal attribution difficult.
Concomitant interventions (daclizumab, donor bone marrow, irradiation, and viral monitoring changes) occurred in overlapping time windows, so “which change caused what” is not identifiable from this design.
Graft-type confounding: liver-containing graft recipients likely differ in baseline severity/urgency; the paper discusses controversy over “liver protective effect” vs non-immunologic risk factors.
Generalizability: highly specialized surgical and immunological protocols at one center limit extrapolation to other settings.
Outcome measurement granularity: the paper reports histopathology-based rejection diagnostics and cumulative hazards, but the study’s era-based changes in diagnostic intensity and clinical triggers for biopsy can affect observed rejection incidence.
These are consistent with the paper’s own statements that reasons for improvement are indeterminate and that efficacy of specific modifications cannot be definitively claimed.
Review scores (BGPT critical rubric)
Short version: moderate scientific quality due to substantial dataset and clear reporting of survival/rejection events, but causal inference limits due to retrospective single-center design and multiple contemporaneous protocol changes.
Author reviews on BGPT
Feedback:
Updated: April 10, 2026
BGPT Paper Review
Study Novelty
70%
Substantial “single-center decade” synthesis of evolving protocols, with reported actuarial long-term outcomes (1/5/10 years) and era-based improvements; however, novelty is incremental relative to broader transplantation progress and prior work from the same group.
Scientific Quality
60%
Strengths: large single-center cohort (155 recipients; 165 grafts), clear reporting of survival, rejection/PTLD/CMV outcomes, and structured discussion of confounding. Red flags/limitations: retrospective observational design; multiple simultaneous protocol changes (daclizumab, bone marrow augmentation, irradiation, viral surveillance) make causal inference weak; graft-type comparisons may be confounded by baseline disease severity/urgency. The paper itself states therapeutic efficacy cannot be definitively claimed for specific modifications.
Study Generality
50%
General insights (infection surveillance, rejection management, the importance of graft type) may transfer, but the specific surgical/immunologic protocol bundle is center-dependent; external validity is uncertain.
Study Usefulness
70%
Practically useful as an outcomes benchmark and as a detailed map of what changed over time and which complications dominated (rejection, PTLD, CMV). Less directly useful for causal selection of any single intervention because of era confounding.
Study Reproducibility
40%
Methods are described (immunosuppression components, monitoring approaches), but full reproducibility would require access to complete protocol details, operational definitions, and full datasets; also, evolving management over the 11-year window complicates exact replication.
Explanatory Depth
60%
The paper provides mechanistic context (e.g., GVHD/rejection concepts, microchimerism discussion in relation to irradiation/bone marrow) and links outcomes to biologic hypotheses, but without direct chimerism/immunologic measurements reported for the human comparison groups, explanatory certainty is limited.
Summarizes the paper’s reported survival and event-rate data into Plotly-ready tables, enabling direct comparison across graft types and eras for downstream statistical modeling.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A simple “liver = immunoprotection” model is unlikely to be sufficient: the paper’s own discussion highlights confounding by disease severity/urgency, and the liver effect may be partially (or largely) explained by baseline risk differences.
A “single adjunct drug” model is unlikely: multiple adjuncts co-occurred with surveillance and operational changes, and the paper cautions that efficacy cannot be definitively claimed for any one modification.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion